Source abstract
Abstract
Elicitation of neutralizing antibody responses against hepatitis C virus (HCV) has been a challenging goal. While the E2 subunit of the HCV envelope glycoprotein complex is a promising target for generating cross-genotype neutralizing antibodies, vaccinations with soluble E2 immunogens generally induce weak neutralizing antibody responses. Here, E2 immunogens (i.e., E2.661 and E2c.661) were loaded into lipid-based nanovaccines and examined for induction of neutralizing antibody responses. Compared with soluble E2 immunogens, E2 nanoparticles elicited 6- to 20-fold higher E2-specific serum IgG titers in mice. Importantly, E2 vaccine nanoparticles analyzed at a single particle level with a flow cytometry-based method revealed interesting dynamics between epitope display on the surfaces of nanoparticles in vitro and induction of neutralizing antibody responses in vivo. E2c.661 nanoparticles that are preferentially bound by a broadly neutralizing antibody, HCV1, in vitro elicit neutralizing antibody responses against both autologous and heterologous HCV virions in vivo. In stark contrast, E2.661 nanoparticles with reduced HCV1-antibody binding in vitro mainly induce autologous neutralizing antibody responses in vivo. These results show that rationale antigen design coupled with interrogation of epitope display on vaccine nanoparticles at a single particle level may aid in vaccine development toward achieving neutralizing antibody responses in vivo.
Source: openalex_inverted_index · Quality: baseline
Affiliations
Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, Michigan 48109, United States
Biointerfaces Institute, University of Michigan, Ann Arbor, Michigan 48109, United States
Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California 92037, United States
Department of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan 48109, United States
Funding
National Heart, Lung, and Blood Institute · National Institute of Allergy and Infectious Diseases · National Institute of Biomedical Imaging and Bioengineering · Alberta Emerald Foundation · U.S. Department of Defense · Division of Chemical, Bioengineering, Environmental, and Transport Systems